Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Immunophenotyping profile of CPG 10101, a new TLR9 agonist antiviral for hepatitis C

John G. McHutchinson, Duke Univ, Durham, NC; Bruce R. Bacon, St. Louis Univ Hopsital, St. Louis, MO; Stuart C. Gordon, Henry Ford Hospital, Detroit, MI; Eric Lawitz, Alamo Medical Research, San Antonio, TX; Mitchell Shiffman, Medical College of Richmond Virginia, Richmond, VA; Nezam H. Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira M. Jacobson, Cornell Univ, New York, NY; Andrew Muir Duke University, Durham, NC; Susan M. Efler, A. Vicari, K. Myette, Nav Ahluwalia, P.P. Murzenok Coley Pharmalbach, Art M. Krieg, Coley Pharmaceutical Group, Ottawa, Canada. Immunophenotyping profile of CPG 10101, a new TLR9 agonist antiviral for hepatitis C. Hepatology. 2005; 42(4):148A.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.